How fast a tumor grows doesn’t solely depend on how quickly the cancer cells can divide, a new study finds.
By examining brain tumors in mice, researchers discovered that immune cells that should be defending the body against disease sometimes end up providing aid and comfort to tumor cells instead. The more immune cells a tumor can recruit to its side, the faster the tumor grows, the researchers find.
Neurofibromatosis and tumors
The findings, which appear in the journal Neuro-Oncology, suggest that targeting immune system cells could potentially slow brain tumor growth in people with the genetic condition neurofibromatosis type 1 (NF1).
“It’s not just all about the tumor cell anymore,” says senior author David H. Gutmann, professor of neurology and director of the Washington University Neurofibromatosis Center at Washington University School of Medicine in St. Louis.
“It’s also about what happens in the tumor environment that drives brain cancer growth. This gives us another way to attack these tumors beyond merely killing the cancer cells—namely, interrupting the communication between tumor cells and immune system cells.”
While people with NF1 usually come to medical attention for birthmarks on their skin, they are also at increased risk of developing tumors. One of the most common of these tumors in children is a low-grade brain tumor called an optic glioma, which affects the optic nerve that connects the brain and the eye. Some of these tumors can cause vision loss.
Unfortunately, NF1 is a notoriously variable disease. Doctors can’t predict what kinds of tumors a person will develop, how fast these tumors will grow, or what types of medical problems the tumors will cause—all of which make it difficult for doctors to decide when a tumor requires chemotherapy and when it is safe to simply watch and wait.
Two kinds of immune cells
To better understand why some tumors grow faster than others, first author Xiaofan Guo, a graduate student in Gutmann’s lab, created five mouse strains with different genetic changes in the NF1 gene and elsewhere in the mouse’s genome.
The five strains varied widely in tumor development and growth. Mice belonging to three of the strains grew tumors starting at about three months of age, with the tumors in one strain of mice growing particularly fast. Members of the fourth strain didn’t grow tumors until they were about six months old, and only a quarter of mice in the fifth strain developed brain tumors on the optic nerve at all.
When the researchers isolated tumor cells from the mice and grew them in a dish, they found little difference in tumor cell growth. The growth rates and other properties of the cancer cells were very similar, no matter which mutation the tumor cells carried.
What did correlate with overall tumor proliferation in mice was the presence of two kinds of immune cells—microglia and T cells—within the tumors. Guo and former postdoctoral research fellow Yuan Pan discovered that the tumor cells themselves were releasing immune system proteins that attracted immune cells to the tumor.
“Cells that should be part of the brain’s defense against tumors have become part of the process of making and growing a tumor,” says Gutmann, who is also a professor of genetics, of neurological surgery, and of pediatrics.
The researchers now are trying to take advantage of this relationship between tumor cells and immune system cells to find new ways to treat brain tumors in people with NF1. One strategy is to slow tumor growth by preventing microglia or T cells from providing support to the cancer cells. However, a more ambitious strategy is to reprogram the T cells to no longer aid tumor cell growth.
“The idea is to use T cells as Trojan horses,” Gutmann says. “These are experiments currently ongoing: We’re trying to change the T cells so that when they enter the brain, instead of promoting the tumor, they shut it down.”
Support for the work came from the National Cancer Institute and the National Institute of Neurological Disorders and Stroke.